查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1887103

實驗室體外診斷 (IVD) 市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察，以及 2024 年至 2032 年的預測

Lab-based IVD Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 140 Pages | 商品交期: 請詢問到貨日

價格

實驗室體外診斷 (IVD) 市場成長驅動因子

全球實驗室體外診斷市場仍然是現代醫療保健的重要支柱，其成長動力主要來自慢性病患病率的上升、傳染病爆發以及全球向精準醫療的轉型。根據最新的產業評估，受醫院和臨床實驗室強勁的診斷需求驅動，該市場到 2024 年的價值將達到 424.2 億美元。預計2025年將達到448.5億美元，到2032年將達到664.1億美元，2025年至2032年的複合年增長率為5.8%。

北美地區憑藉其先進的醫療保健基礎設施、高診斷檢測率以及羅氏、雅培、賽默飛世爾科技和BD等主要廠商的存在，將在2024年佔全球市場39.39%的佔有率。對快速、可靠和高度準確的診斷結果日益增長的需求，正在加速對自動化檢測平台、分子診斷和下一代定序技術的投資。

市場驅動因素

實驗室體外診斷市場的主要驅動因素是全球慢性病和傳染病負擔的日益惡化。根據世界衛生組織（世衛組織）的數據，2023年將有820萬人被診斷出患有結核病（TB），2022年將有750萬人被診斷出患有結核病，這表明全球對結核病篩檢的需求日益增長。此外，世衛組織報告稱，2024年將有2.54億例乙型肝炎病例和5000萬例丙型肝炎病例，這將進一步推動對常規實驗室檢測的需求。

在新興市場和已開發市場，實驗室診斷工具的可及性持續改善，這得益於人們對早期疾病檢測意識的提高、篩檢項目的增加以及諸如世衛組織2023年基本診斷清單（EDL）等公共衛生舉措的推動。人口老化也加劇了診斷需求，因為老年人更容易患上需要定期監測的慢性病和傳染病。

市場限制因子

儘管市場具有很高的成長潛力，但由於一些新興市場不利的報銷政策，該市場仍面臨挑戰。基因和分子診斷測試的高昂成本限制了其在非洲、巴西和亞洲部分地區的普及。在中國，省級層級採用不同的報銷代碼，導致診斷應用出現延遲和不一致。這些因素共同阻礙了先進體外診斷醫療器材（IVD）系統的大規模應用。

市場機會

一個關鍵機會在於分子診斷（包括次世代定序 (NGS) 和基於 PCR 的技術）的日益普及。各公司正積極尋求 FDA 批准和全球監管認證，以增強其分子檢測產品組合。例如，DiaSorin 的 "Simplex COVID-19 & Flu A/B Direct" 檢測試劑盒於 2023 年獲得 FDA 批准，進一步拓展了其高價值分子檢測產品線。從傳統診斷轉向分子精準診斷工具，正在為改善癌症檢測、病毒量測量和基因篩檢開闢新的途徑。

市場趨勢

實驗室體外診斷市場的一大趨勢是自動化和數位化在實驗室工作流程中的應用日益廣泛。自動化PCR系統、人工智慧分析儀和先進的血液學系統正在提高檢測準確性並縮短週轉時間。 2025年4月，Seegene公司宣布開發其下一代自動化平台“CURECA”，旨在簡化全球PCR檢測流程。

此外，多家公司正在投資個人化診斷解決方案。 2024年2月，Quest Diagnostics推出了MelaNodal Predict，這是一款人工智慧輔助的基因表現檢測產品，用於個人化黑色素瘤治療指導。

依細分市場概述

依產品類型劃分

2024年，由於監管審批的增加和檢測量的擴大，試劑和耗材佔了市場主導地位。預計到 2032 年，設備領域將保持穩定成長，這主要得益於快速檢測設備和先進 PCR 系統的日益普及。

依技術劃分

2024 年，免疫診斷領域佔市場主導地位，這主要得益於羅氏 Elexis HBeAg 定量檢測等新型檢測方法的推出。分子診斷領域佔第二大市場佔有率，這主要得益於基於 PCR 的解決方案和新一代定序應用的興起。

依樣本類型劃分

預計血液學檢測將在 2024 年佔市場主導地位，並因其在急性傳染病、腫瘤和慢性病評估中的廣泛應用而實現最高的複合年增長率。

依應用程式劃分

傳染病領域在 2024 年仍將保持領先地位，這主要得益於結核病、愛滋病和肝炎等疾病在全球範圍內造成的沉重疾病負擔。由於癌症病例數量不斷增加以及高靈敏度癌症檢測技術的推出，腫瘤領域預計將以第二高的複合年增長率增長。

依最終使用者劃分

2024年，臨床實驗室在體外診斷(IVD)市場佔主導地位，這主要得益於龐大的患者數量和先進的檢測能力。由於慢性病住院率的上升，醫院的需求持續強勁。

區域洞察

北美

2024年，北美持續維持市場領先地位，市場規模達到167.1億美元，主要得益於先進的醫療標準和FDA持續核准的產品。

歐洲

2024年，歐洲位居第二，這主要得益於慢性病的普遍存在以及西門子醫療、希森美康和羅氏等公司的強勁創新勢頭。

亞太地區

預計到2032年，亞太地區將維持最高的複合年增長率，這主要得益於人們對早期診斷意識的提高以及產品上市數量的增加，其中包括雅培公司於2024年推出的Alinity i.免疫分析模組。

拉丁美洲、中東和非洲

這些地區正經歷穩定成長，這主要得益於結核病病例的增加以及自動化化學和血液分析儀的日益普及。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 各國及次區域主要疾病流行情形（2023/2024）
  • 實驗室體外診斷產品的技術進步
  • 主要公司新產品發布
  • 主要產業趨勢（併購、合作及其他）

第五章：全球實驗室體外診斷 (IVD) 市場分析、洞察與預測 (2019-2032)

  • 市場分析、洞察與預測 - 依產品類型劃分
    • 儀器
    • 試劑和耗材
  • 市場分析、洞察與預測 - 依技術劃分
    • 免疫診斷
      • 酵素連結免疫吸附試驗 (ELISA)
      • 螢光免疫分析 (FIA)
      • 快速偵測
      • 其他
    • 臨床化學
      • 電解質檢測
      • 基礎與綜合代謝指標檢測
      • 肝功能檢測
      • 腎功能檢測
      • 血脂檢測
      • 其他
    • 分子檢測診斷
      • 聚合酶鍊式反應 (PCR)
      • 原位雜交
      • DNA定序與次世代定序
      • 其他
    • 血液學
    • 其他
  • 市場分析、洞察與預測 - 依樣本類型劃分
    • 血液
    • 尿液
    • 唾液
    • 組織
    • 其他
  • 市場分析、洞察與預測 - 依應用領域劃分
    • 傳染病
    • 心臟病學
    • 腫瘤學
    • 胃腸病學
    • 過敏症
    • 自體免疫疾病
    • 產前篩檢
    • 其他
  • 市場分析、洞察與預測 - 依最終用途劃分用戶
    • 醫院
    • 臨床實驗室
    • 其他
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美實驗室體外診斷 (IVD) 市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲實驗室體外診斷 (IVD) 市場分析、洞察與預測 (2019-2032)

  • 依國家/地區
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區實驗室體外診斷 (IVD) 市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲實驗室體外診斷 (IVD) 市場分析、洞察與預測 (2019-2032)

  • 依國家/地區
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東和非洲實驗室體外診斷 (IVD) 市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析 (2024)
  • 公司簡介
    • F.霍夫曼-拉羅氏有限公司
    • 雅培
    • 賽默飛世爾科技公司
    • 希森美康公司
    • 西門子 Healthineers AG
    • BD
    • 凱傑
    • Bio-Rad 實驗室有限公司
    • Seegene 公司
    • DiaSorin S.p.A.
    • Quest Diagnostics 公司
Product Code: FBI112985

Growth Factors of lab-based in vitro diagnostics (IVD) Market

The global lab-based in vitro diagnostics (IVD) market remains a foundational pillar of modern healthcare, driven by rising chronic disease prevalence, infectious disease outbreaks, and the global shift toward precision medicine. According to the latest industry assessment, the market was valued at USD 42.42 billion in 2024, supported by strong diagnostic demand across hospitals and clinical laboratories. The market is expected to increase to USD 44.85 billion in 2025, eventually reaching USD 66.41 billion by 2032, advancing at a CAGR of 5.8% throughout 2025-2032.

North America dominated the global market with 39.39% share in 2024, attributed to its advanced healthcare infrastructure, high diagnostic testing rates, and the presence of leading companies such as Roche, Abbott, Thermo Fisher Scientific, and BD. The rising need for rapid, reliable, and high-precision diagnostic results is accelerating investment in automated testing platforms, molecular diagnostics, and next-generation sequencing technologies.

Market Drivers

A key driver for the lab-based IVD market is the growing global burden of chronic and infectious diseases. According to WHO, 8.2 million people were diagnosed with tuberculosis (TB) in 2023, up from 7.5 million in 2022, indicating heightened screening needs worldwide. Additionally, WHO reported in 2024 that 254 million individuals were living with hepatitis B and 50 million with hepatitis C, further boosting demand for routine laboratory testing.

Growing awareness of early disease detection, increasing screening programs, and public health initiatives-such as the WHO's 2023 Essential Diagnostics List (EDL)-continue to improve access to lab-based diagnostic tools across emerging and developed markets. The expanding geriatric population further contributes to diagnostic demand, as elderly individuals are more susceptible to chronic and infectious diseases requiring regular monitoring.

Market Restraints

Despite strong growth potential, the market faces challenges from unfavorable reimbursement policies in several emerging markets. The high cost of genetic and molecular diagnostic tests limits adoption in regions such as Africa, Brazil, and parts of Asia. In China, reimbursement occurs at the provincial level with differing codes, creating delays and inconsistency in diagnostic uptake. These factors collectively restrict large-scale penetration of advanced IVD systems.

Market Opportunities

Major opportunities lie in the rising adoption of molecular diagnostics, including next-generation sequencing (NGS) and PCR-based technologies. Companies are increasingly pursuing FDA approvals and global regulatory certifications to strengthen their molecular testing portfolios. For example, DiaSorin S.p.A. received FDA approval for its Simplex COVID-19 & Flu A/B Direct assay in 2023, expanding its high-value molecular pipeline. The shift from traditional diagnostics to molecular precision tools opens pathways for improved cancer detection, viral load testing, and genetic screening.

Market Trends

A significant trend in the lab-based IVD market is the rising integration of automation and digitalization in laboratory workflows. Automated PCR systems, AI-enabled analyzers, and advanced hematology systems are improving test accuracy and turnaround time. In April 2025, Seegene Inc. announced development of its next-generation automation platform, CURECA, designed to streamline PCR testing processes globally.

Additionally, several companies are investing in personalized diagnostic solutions. In February 2024, Quest Diagnostics launched MelaNodal Predict, an AI-supported gene expression test for personalized melanoma treatment guidance.

Segmental Overview

By Product Type

Reagents & consumables dominated the market in 2024 due to increasing regulatory approvals and growing test volumes. The instruments segment is projected to grow steadily through 2032 with rising adoption of rapid testing devices and advanced PCR systems.

By Technique

Immunodiagnostics led the market in 2024, supported by new assay launches such as Roche's Elecsys HBeAg quant test. The molecular diagnostics segment held the second-largest share, fueled by the growing number of PCR-based solutions and next-generation sequencing applications.

By Sample Type

Blood-based tests dominated the market in 2024 and are expected to grow at the highest CAGR due to widespread usage in acute infections, oncology, and chronic disease assessments.

By Application

Infectious diseases remained the leading segment in 2024, supported by high global burdens of TB, HIV, and hepatitis. Oncology is expected to grow at the second-highest CAGR due to rising cancer cases and the launch of highly sensitive cancer assays.

By End-User

Clinical laboratories dominated the IVD market in 2024, driven by high patient volumes and advanced testing capabilities. Hospitals continued to support significant demand due to increasing hospitalization rates for chronic diseases.

Regional Insights

North America

North America generated USD 16.71 billion in 2024, maintaining market leadership through advanced healthcare standards and continuous product approvals from the FDA.

Europe

Europe ranked second in 2024, supported by chronic disease prevalence and strong innovation momentum from Siemens Healthineers, Sysmex, and Roche.

Asia Pacific

Asia Pacific is expected to record the fastest CAGR through 2032 due to rising early-diagnosis awareness and increased product launches, including Abbott's Alinity i immunoassay module in 2024.

Latin America & Middle East & Africa

These regions show steady growth supported by rising TB cases and increasing adoption of automated chemistry and hematology analyzers.

Conclusion

With the market rising from USD 42.42 billion in 2024 to USD 66.41 billion in 2032, the global lab-based IVD industry is set for significant expansion. Growing infectious disease screening, rapid adoption of molecular diagnostics, automation improvements, and strategic partnerships across companies will continue shaping the future of clinical diagnostics worldwide.

Segmentation By Product Type

  • Instruments
  • Reagents & Consumables

By Technique

  • Immunodiagnostics
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Fluorescence Immunoassay (FIA)
    • Rapid test
    • Others
  • Clinical Chemistry
    • Electrolyte Panel
    • Basic and Comprehensive Metabolic Panels
    • Liver Tests
    • Renal Tests
    • Lipid Panel
    • Others
  • Molecular Diagnostics
    • Polymerase Chain Reaction (PCR)
    • In Situ Hybridization
    • DNA Sequencing & Next-Generation Sequencing
    • Others
  • Hematology
  • Others

By Sample Type

  • Blood
  • Urine
  • Saliva
  • Tissue
  • Others

By Application

  • Infectious Diseases
  • Cardiology
  • Oncology
  • Gastroenterology
  • Allergy
  • Autoimmunity
  • Prenatal Screening
  • Others

By End-user

  • Hospitals
  • Clinical Laboratories
  • Others

By Region

  • North America (By Product Type, By Technique, By Sample Type, By Application, By End-user, and By Country/Sub-Region)
    • U.S.
    • Canada
  • Europe (By Product Type, By Technique, By Sample Type, By Application, By End-user, and By Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product Type, By Technique, By Sample Type, By Application, By End-user, and By Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product Type, By Technique, By Sample Type, By Application, By End-user, and By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product Type, By Technique, By Sample Type, By Application, By End-user, and By Country/Sub-Region)
    • GCC
    • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, by Key Countries/Sub-regions, 2023/2024
  • 4.2. Technological Advancements in Lab-based IVD Products
  • 4.3. New Product Launches, by Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Instruments
    • 5.1.2. Reagents & Consumables
  • 5.2. Market Analysis, Insights and Forecast - By Technique
    • 5.2.1. Immunodiagnostics
      • 5.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
      • 5.2.1.2. Fluorescence immunoassay (FIA)
      • 5.2.1.3. Rapid test
      • 5.2.1.4. Others
    • 5.2.2. Clinical Chemistry
      • 5.2.2.1. Electrolyte Panel
      • 5.2.2.2. Basic and Comprehensive Metabolic Panels
      • 5.2.2.3. Liver Tests
      • 5.2.2.4. Renal Tests
      • 5.2.2.5. Lipid Panel
      • 5.2.2.6. Others
    • 5.2.3. Molecular Diagnostics
      • 5.2.3.1. Polymerase Chain Reaction (PCR)
      • 5.2.3.2. In Situ Hybridization
      • 5.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 5.2.3.4. Others
    • 5.2.4. Hematology
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Sample Type
    • 5.3.1. Blood
    • 5.3.2. Urine
    • 5.3.3. Saliva
    • 5.3.4. Tissue
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Application
    • 5.4.1. Infectious Diseases
    • 5.4.2. Cardiology
    • 5.4.3. Oncology
    • 5.4.4. Gastroenterology
    • 5.4.5. Allergy
    • 5.4.6. Autoimmunity
    • 5.4.7. Prenatal Screening
    • 5.4.8. Others
  • 5.5. Market Analysis, Insights and Forecast - By End-user
    • 5.5.1. Hospitals
    • 5.5.2. Clinical Laboratories
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Instruments
    • 6.1.2. Reagents & Consumables
  • 6.2. Market Analysis, Insights and Forecast - By Technique
    • 6.2.1. Immunodiagnostics
      • 6.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
      • 6.2.1.2. Fluorescence immunoassay (FIA)
      • 6.2.1.3. Rapid test
      • 6.2.1.4. Others
    • 6.2.2. Clinical Chemistry
      • 6.2.2.1. Electrolyte Panel
      • 6.2.2.2. Basic and Comprehensive Metabolic Panels
      • 6.2.2.3. Liver Tests
      • 6.2.2.4. Renal Tests
      • 6.2.2.5. Lipid Panel
      • 6.2.2.6. Others
    • 6.2.3. Molecular Diagnostics
      • 6.2.3.1. Polymerase Chain Reaction (PCR)
      • 6.2.3.2. In Situ Hybridization
      • 6.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 6.2.3.4. Others
    • 6.2.4. Hematology
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Sample Type
    • 6.3.1. Blood
    • 6.3.2. Urine
    • 6.3.3. Saliva
    • 6.3.4. Tissue
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By Application
    • 6.4.1. Infectious Diseases
    • 6.4.2. Cardiology
    • 6.4.3. Oncology
    • 6.4.4. Gastroenterology
    • 6.4.5. Allergy
    • 6.4.6. Autoimmunity
    • 6.4.7. Prenatal Screening
    • 6.4.8. Others
  • 6.5. Market Analysis, Insights and Forecast - By End-user
    • 6.5.1. Hospitals
    • 6.5.2. Clinical Laboratories
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Instruments
    • 7.1.2. Reagents & Consumables
  • 7.2. Market Analysis, Insights and Forecast - By Technique
    • 7.2.1. Immunodiagnostics
      • 7.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
      • 7.2.1.2. Fluorescence immunoassay (FIA)
      • 7.2.1.3. Rapid test
      • 7.2.1.4. Others
    • 7.2.2. Clinical Chemistry
      • 7.2.2.1. Electrolyte Panel
      • 7.2.2.2. Basic and Comprehensive Metabolic Panels
      • 7.2.2.3. Liver Tests
      • 7.2.2.4. Renal Tests
      • 7.2.2.5. Lipid Panel
      • 7.2.2.6. Others
    • 7.2.3. Molecular Diagnostics
      • 7.2.3.1. Polymerase Chain Reaction (PCR)
      • 7.2.3.2. In Situ Hybridization
      • 7.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 7.2.3.4. Others
    • 7.2.4. Hematology
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Sample Type
    • 7.3.1. Blood
    • 7.3.2. Urine
    • 7.3.3. Saliva
    • 7.3.4. Tissue
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By Application
    • 7.4.1. Infectious Diseases
    • 7.4.2. Cardiology
    • 7.4.3. Oncology
    • 7.4.4. Gastroenterology
    • 7.4.5. Allergy
    • 7.4.6. Autoimmunity
    • 7.4.7. Prenatal Screening
    • 7.4.8. Others
  • 7.5. Market Analysis, Insights and Forecast - By End-user
    • 7.5.1. Hospitals
    • 7.5.2. Clinical Laboratories
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.6.1. Germany
    • 7.6.2. U.K.
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Instruments
    • 8.1.2. Reagents & Consumables
  • 8.2. Market Analysis, Insights and Forecast - By Technique
    • 8.2.1. Immunodiagnostics
      • 8.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
      • 8.2.1.2. Fluorescence immunoassay (FIA)
      • 8.2.1.3. Rapid test
      • 8.2.1.4. Others
    • 8.2.2. Clinical Chemistry
      • 8.2.2.1. Electrolyte Panel
      • 8.2.2.2. Basic and Comprehensive Metabolic Panels
      • 8.2.2.3. Liver Tests
      • 8.2.2.4. Renal Tests
      • 8.2.2.5. Lipid Panel
      • 8.2.2.6. Others
    • 8.2.3. Molecular Diagnostics
      • 8.2.3.1. Polymerase Chain Reaction (PCR)
      • 8.2.3.2. In Situ Hybridization
      • 8.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 8.2.3.4. Others
    • 8.2.4. Hematology
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Sample Type
    • 8.3.1. Blood
    • 8.3.2. Urine
    • 8.3.3. Saliva
    • 8.3.4. Tissue
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By Application
    • 8.4.1. Infectious Diseases
    • 8.4.2. Cardiology
    • 8.4.3. Oncology
    • 8.4.4. Gastroenterology
    • 8.4.5. Allergy
    • 8.4.6. Autoimmunity
    • 8.4.7. Prenatal Screening
    • 8.4.8. Others
  • 8.5. Market Analysis, Insights and Forecast - By End-user
    • 8.5.1. Hospitals
    • 8.5.2. Clinical Laboratories
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Instruments
    • 9.1.2. Reagents & Consumables
  • 9.2. Market Analysis, Insights and Forecast - By Technique
    • 9.2.1. Immunodiagnostics
      • 9.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
      • 9.2.1.2. Fluorescence immunoassay (FIA)
      • 9.2.1.3. Rapid test
      • 9.2.1.4. Others
    • 9.2.2. Clinical Chemistry
      • 9.2.2.1. Electrolyte Panel
      • 9.2.2.2. Basic and Comprehensive Metabolic Panels
      • 9.2.2.3. Liver Tests
      • 9.2.2.4. Renal Tests
      • 9.2.2.5. Lipid Panel
      • 9.2.2.6. Others
    • 9.2.3. Molecular Diagnostics
      • 9.2.3.1. Polymerase Chain Reaction (PCR)
      • 9.2.3.2. In Situ Hybridization
      • 9.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 9.2.3.4. Others
    • 9.2.4. Hematology
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Sample Type
    • 9.3.1. Blood
    • 9.3.2. Urine
    • 9.3.3. Saliva
    • 9.3.4. Tissue
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By Application
    • 9.4.1. Infectious Diseases
    • 9.4.2. Cardiology
    • 9.4.3. Oncology
    • 9.4.4. Gastroenterology
    • 9.4.5. Allergy
    • 9.4.6. Autoimmunity
    • 9.4.7. Prenatal Screening
    • 9.4.8. Others
  • 9.5. Market Analysis, Insights and Forecast - By End-user
    • 9.5.1. Hospitals
    • 9.5.2. Clinical Laboratories
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. Instruments
    • 10.1.2. Reagents & Consumables
  • 10.2. Market Analysis, Insights and Forecast - By Technique
    • 10.2.1. Immunodiagnostics
      • 10.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
      • 10.2.1.2. Fluorescence immunoassay (FIA)
      • 10.2.1.3. Rapid test
      • 10.2.1.4. Others
    • 10.2.2. Clinical Chemistry
      • 10.2.2.1. Electrolyte Panel
      • 10.2.2.2. Basic and Comprehensive Metabolic Panels
      • 10.2.2.3. Liver Tests
      • 10.2.2.4. Renal Tests
      • 10.2.2.5. Lipid Panel
      • 10.2.2.6. Others
    • 10.2.3. Molecular Diagnostics
      • 10.2.3.1. Polymerase Chain Reaction (PCR)
      • 10.2.3.2. In Situ Hybridization
      • 10.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 10.2.3.4. Others
    • 10.2.4. Hematology
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Sample Type
    • 10.3.1. Blood
    • 10.3.2. Urine
    • 10.3.3. Saliva
    • 10.3.4. Tissue
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By Application
    • 10.4.1. Infectious Diseases
    • 10.4.2. Cardiology
    • 10.4.3. Oncology
    • 10.4.4. Gastroenterology
    • 10.4.5. Allergy
    • 10.4.6. Autoimmunity
    • 10.4.7. Prenatal Screening
    • 10.4.8. Others
  • 10.5. Market Analysis, Insights and Forecast - By End-user
    • 10.5.1. Hospitals
    • 10.5.2. Clinical Laboratories
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. F. Hoffmann-La Roche Ltd.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. Financials (Based on Availability)
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. SWOT,Etc.
    • 11.2.2. Abbott
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. Financials (Based on Availability)
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. SWOT,Etc.
    • 11.2.3. Thermo Fisher Scientific Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. Financials (Based on Availability)
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. SWOT,Etc.
    • 11.2.4. Sysmex Corporation
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. Financials (Based on Availability)
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. SWOT,Etc.
    • 11.2.5. Siemens Healthineers AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. Financials (Based on Availability)
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. SWOT,Etc.
    • 11.2.6. BD
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. Financials (Based on Availability)
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. SWOT,Etc.
    • 11.2.7. QIAGEN
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. Financials (Based on Availability)
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. SWOT,Etc.
    • 11.2.8. Bio-Rad Laboratories, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. Financials (Based on Availability)
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. SWOT,Etc.
    • 11.2.9. Seegene Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. Financials (Based on Availability)
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. SWOT,Etc.
    • 11.2.10. DiaSorin S.p.A.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. Financials (Based on Availability)
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. SWOT,Etc.
    • 11.2.11. Quest Diagnostics Incorporated
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. Financials (Based on Availability)
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. SWOT,Etc.

List of Tables

  • Table 1: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 2: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
  • Table 3: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
  • Table 4: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
  • Table 5: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
  • Table 6: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
  • Table 7: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 8: Global Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
  • Table 9: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 10: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 11: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
  • Table 12: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
  • Table 13: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
  • Table 14: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
  • Table 15: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
  • Table 16: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 17: North America Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
  • Table 18: North America Lab-based IVD Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 19: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 20: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
  • Table 21: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
  • Table 22: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
  • Table 23: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
  • Table 24: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
  • Table 25: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 26: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
  • Table 27: Europe Lab-based IVD Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 28: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 29: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
  • Table 30: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
  • Table 31: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
  • Table 32: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
  • Table 33: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
  • Table 34: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 35: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
  • Table 36: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 37: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 38: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
  • Table 39: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
  • Table 40: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
  • Table 41: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
  • Table 42: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
  • Table 43: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 44: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
  • Table 45: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 46: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 47: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
  • Table 48: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
  • Table 49: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
  • Table 50: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
  • Table 51: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
  • Table 52: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 53: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
  • Table 54: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Lab-based IVD Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Lab-based IVD Market Value Share (%), by Product Type, 2024 & 2032
  • Figure 3: Global Lab-based IVD Market Value Share (%), by Technique, 2024 & 2032
  • Figure 4: Global Lab-based IVD Market Value Share (%), by Sample Type 2024 & 2032
  • Figure 5: Global Lab-based IVD Market Value Share (%), by Application, 2024 & 2032
  • Figure 6: Global Lab-based IVD Market Value Share (%), by End-user, 2024 & 2032
  • Figure 7: Global Lab-based IVD Market Value (USD billion), by Region, 2024 & 2032
  • Figure 8: North America Lab-based IVD Market Value (USD billion), by Product Type, 2024 & 2032
  • Figure 9: North America Lab-based IVD Market Value Share (%), by Product Type, 2024
  • Figure 10: North America Lab-based IVD Market Value (USD billion), by Technique, 2024 & 2032
  • Figure 11: North America Lab-based IVD Market Value Share (%), by Technique, 2024
  • Figure 12: North America Lab-based IVD Market Value (USD billion), by Sample Type, 2024 & 2032
  • Figure 13: North America Lab-based IVD Market Value Share (%), by Sample Type, 2024
  • Figure 14: North America Lab-based IVD Market Value (USD billion), by Application, 2024 & 2032
  • Figure 15: North America Lab-based IVD Market Value Share (%), by Application, 2024
  • Figure 16: North America Lab-based IVD Market Value (USD billion), by End-user, 2024 & 2032
  • Figure 17: North America Lab-based IVD Market Value Share (%), by End-user, 2024
  • Figure 18: North America Lab-based IVD Market Value (USD billion), By Country, 2024 & 2032
  • Figure 19: North America Lab-based IVD Market Value Share (%), By Country, 2024
  • Figure 20: Europe Lab-based IVD Market Value (USD billion), by Product Type, 2024 & 2032
  • Figure 21: Europe Lab-based IVD Market Value Share (%), by Product Type, 2024
  • Figure 22: Europe Lab-based IVD Market Value (USD billion), by Technique, 2024 & 2032
  • Figure 23: Europe Lab-based IVD Market Value Share (%), by Technique, 2024
  • Figure 24: Europe Lab-based IVD Market Value (USD billion), by Sample Type, 2024 & 2032
  • Figure 25: Europe Lab-based IVD Market Value Share (%), by Sample Type, 2024
  • Figure 26: Europe Lab-based IVD Market Value (USD billion), by Application, 2024 & 2032
  • Figure 27: Europe Lab-based IVD Market Value Share (%), by Application, 2024
  • Figure 28: Europe Lab-based IVD Market Value (USD billion), by End-user, 2024 & 2032
  • Figure 29: Europe Lab-based IVD Market Value Share (%), by End-user, 2024
  • Figure 30: Europe Lab-based IVD Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 31: Europe Lab-based IVD Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 32: Asia Pacific Lab-based IVD Market Value (USD billion), by Product Type, 2024 & 2032
  • Figure 33: Asia Pacific Lab-based IVD Market Value Share (%), by Product Type, 2024
  • Figure 34: Asia Pacific Lab-based IVD Market Value (USD billion), by Technique, 2024 & 2032
  • Figure 35: Asia Pacific Lab-based IVD Market Value Share (%), by Technique, 2024
  • Figure 36: Asia Pacific Lab-based IVD Market Value (USD billion), by Sample Type, 2024 & 2032
  • Figure 37: Asia Pacific Lab-based IVD Market Value Share (%), by Sample Type, 2024
  • Figure 38: Asia Pacific Lab-based IVD Market Value (USD billion), by Application, 2024 & 2032
  • Figure 39: Asia Pacific Lab-based IVD Market Value Share (%), by Application, 2024
  • Figure 40: Asia Pacific Lab-based IVD Market Value (USD billion), by End-user, 2024 & 2032
  • Figure 41: Asia Pacific Lab-based IVD Market Value Share (%), by End-user, 2024
  • Figure 42: Asia Pacific Lab-based IVD Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 43: Asia Pacific Lab-based IVD Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 44: Latin America Lab-based IVD Market Value (USD billion), by Product Type, 2024 & 2032
  • Figure 45: Latin America Lab-based IVD Market Value Share (%), by Product Type, 2024
  • Figure 46: Latin America Lab-based IVD Market Value (USD billion), by Technique, 2024 & 2032
  • Figure 47: Latin America Lab-based IVD Market Value Share (%), by Technique, 2024
  • Figure 48: Latin America Lab-based IVD Market Value (USD billion), by Sample Type, 2024 & 2032
  • Figure 49: Latin America Lab-based IVD Market Value Share (%), by Sample Type, 2024
  • Figure 50: Latin America Lab-based IVD Market Value (USD billion), by Application, 2024 & 2032
  • Figure 51: Latin America Lab-based IVD Market Value Share (%), by Application, 2024
  • Figure 52: Latin America Lab-based IVD Market Value (USD billion), by End-user, 2024 & 2032
  • Figure 53: Latin America Lab-based IVD Market Value Share (%), by End-user, 2024
  • Figure 54: Latin America Lab-based IVD Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 55: Latin America Lab-based IVD Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 56: Middle East & Africa Lab-based IVD Market Value (USD billion), by Product Type, 2024 & 2032
  • Figure 57: Middle East & Africa Lab-based IVD Market Value Share (%), by Product Type, 2024
  • Figure 58: Middle East & Africa Lab-based IVD Market Value (USD billion), by Technique, 2024 & 2032
  • Figure 59: Middle East & Africa Lab-based IVD Market Value Share (%), by Technique, 2024
  • Figure 60: Middle East & Africa Lab-based IVD Market Value (USD billion), by Sample Type, 2024 & 2032
  • Figure 61: Middle East & Africa Lab-based IVD Market Value Share (%), by Sample Type, 2024
  • Figure 62: Middle East & Africa Lab-based IVD Market Value (USD billion), by Application, 2024 & 2032
  • Figure 63: Middle East & Africa Lab-based IVD Market Value Share (%), by Application, 2024
  • Figure 64: Middle East & Africa Lab-based IVD Market Value (USD billion), by End-user, 2024 & 2032
  • Figure 65: Middle East & Africa Lab-based IVD Market Value Share (%), by End-user, 2024
  • Figure 66: Middle East & Africa Lab-based IVD Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 67: Middle East & Africa Lab-based IVD Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 68: Global Lab-based IVD Market Share (%), By Company, 2024